164 related articles for article (PubMed ID: 15289503)
1. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83.
Zinser E; Lechmann M; Golka A; Lutz MB; Steinkasserer A
J Exp Med; 2004 Aug; 200(3):345-51. PubMed ID: 15289503
[TBL] [Abstract][Full Text] [Related]
2. Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: implications for a lack of therapeutic potential.
Pashine A; Göpfert U; Chen J; Hoffmann E; Dietrich PS; Peng SL
Immunol Lett; 2008 Jan; 115(1):9-15. PubMed ID: 18079004
[TBL] [Abstract][Full Text] [Related]
3. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts.
Xu JF; Huang BJ; Yin H; Xiong P; Feng W; Xu Y; Fang M; Zheng F; Wang CY; Gong FL
Transpl Int; 2007 Mar; 20(3):266-76. PubMed ID: 17291220
[TBL] [Abstract][Full Text] [Related]
4. MCS-18, a novel natural product isolated from Helleborus purpurascens, inhibits dendritic cell activation and prevents autoimmunity as shown in vivo using the EAE model.
Horstmann B; Zinser E; Turza N; Kerek F; Steinkasserer A
Immunobiology; 2007; 212(9-10):839-53. PubMed ID: 18086383
[TBL] [Abstract][Full Text] [Related]
5. CD83: a regulatory molecule of the immune system with great potential for therapeutic application.
Fujimoto Y; Tedder TF
J Med Dent Sci; 2006 Jun; 53(2):85-91. PubMed ID: 16913569
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic expression of functionally active recombinant soluble CD83 from HEK 293T cells.
Staab C; Mühl-Zürbes P; Steinkasserer A; Kummer M
Immunobiology; 2010; 215(9-10):849-54. PubMed ID: 20576314
[TBL] [Abstract][Full Text] [Related]
7. Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.
Zinser E; Naumann R; Wild AB; Michalski J; Deinzer A; Stich L; Kuhnt C; Steinkasserer A; Knippertz I
Front Immunol; 2019; 10():1442. PubMed ID: 31293592
[TBL] [Abstract][Full Text] [Related]
8. The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells.
Kotzor N; Lechmann M; Zinser E; Steinkasserer A
Immunobiology; 2004; 209(1-2):129-40. PubMed ID: 15481147
[TBL] [Abstract][Full Text] [Related]
9. CNI-1493 mediated suppression of dendritic cell activation in vitro and in vivo.
Zinser E; Turza N; Steinkasserer A
Immunobiology; 2004; 209(1-2):89-97. PubMed ID: 15481144
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
11. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells.
Ellestad KK; Tsutsui S; Noorbakhsh F; Warren KG; Yong VW; Pittman QJ; Power C
J Immunol; 2009 Jul; 183(1):298-309. PubMed ID: 19542441
[TBL] [Abstract][Full Text] [Related]
12. Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE).
Yura M; Takahashi I; Serada M; Koshio T; Nakagami K; Yuki Y; Kiyono H
J Autoimmun; 2001 Aug; 17(1):17-25. PubMed ID: 11488634
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Ge Z; Da Y; Xue Z; Zhang K; Zhuang H; Peng M; Li Y; Li W; Simard A; Hao J; Yao Z; Zhang R
Exp Neurol; 2013 Mar; 241():56-66. PubMed ID: 23261766
[TBL] [Abstract][Full Text] [Related]
14. Taenia crassiceps infection abrogates experimental autoimmune encephalomyelitis.
Reyes JL; Espinoza-Jiménez AF; González MI; Verdin L; Terrazas LI
Cell Immunol; 2011; 267(2):77-87. PubMed ID: 21185554
[TBL] [Abstract][Full Text] [Related]
15. CD83 orchestrates immunity toward self and non-self in dendritic cells.
Wild AB; Krzyzak L; Peckert K; Stich L; Kuhnt C; Butterhof A; Seitz C; Mattner J; Grüner N; Gänsbauer M; Purtak M; Soulat D; Winkler TH; Nitschke L; Zinser E; Steinkasserer A
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31527313
[TBL] [Abstract][Full Text] [Related]
16. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.
Lechmann M; Kremmer E; Sticht H; Steinkasserer A
Protein Expr Purif; 2002 Apr; 24(3):445-52. PubMed ID: 11922761
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic activity of soluble CD83: comments on Pashine et al.
Chou CP
Immunol Lett; 2008 Jan; 115(1):20. PubMed ID: 18093663
[No Abstract] [Full Text] [Related]
18. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells.
Lechmann M; Krooshoop DJ; Dudziak D; Kremmer E; Kuhnt C; Figdor CG; Schuler G; Steinkasserer A
J Exp Med; 2001 Dec; 194(12):1813-21. PubMed ID: 11748282
[TBL] [Abstract][Full Text] [Related]
19. Activated T cells induce rapid CD83 expression on B cells by engagement of CD40.
Kretschmer B; Kühl S; Fleischer B; Breloer M
Immunol Lett; 2011 May; 136(2):221-7. PubMed ID: 21277328
[TBL] [Abstract][Full Text] [Related]
20. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
Cross AH; Girard TJ; Giacoletto KS; Evans RJ; Keeling RM; Lin RF; Trotter JL; Karr RW
J Clin Invest; 1995 Jun; 95(6):2783-9. PubMed ID: 7539461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
